TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01818362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA NP+M1
Description: MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 NP+M1
Description: ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 NP+M1
Description: ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 NP+M1
Description: ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 NP+M1
Description: ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 NP+M1
Description: ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
Study: NCT01632371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon + Scoring Balloon
Description: Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Eluting Balloon
Description: Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
Study: NCT00512096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: 175 mg/m\^2 By Vein Over 3 Hours on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
Study: NCT00649181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets 5 mg
Description: 2x5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaroloxyn® Tablets 5 mg
Description: 2x5mg, single dose fasting
Study: NCT03461627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Xinafoate and Fluticasone Propinate Powder
Description: 50ug/250ug 1 puff twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: 50ug/250ug 1 puff twice a day for 4 weeks
Study: NCT01546948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
Study: NCT01384058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: ezetimibe 10 mg per day for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Simvastatin 20 mg per day for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10/Simvastatin 20
Description: Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
Study: NCT01945515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training
Description: Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Robotic-assisted gait training
Description: Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
Study: NCT01343160

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® VIABIL® Biliary Endoprosthesis
Description: Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
Study: NCT01027793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin cream 0.005%
Description: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Dermabrasion
Description: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
Study: NCT02069561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Description: Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
Study: NCT03337724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Study: NCT01201252

Intervention type: PROCEDURE
Intervention: Stool sampling
Description: Stool samples will be collected, tested and genotyped for the presence of rotavirus
Study: NCT00773097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 - Poly ICLC
Description: The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
Study: NCT00396318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: 2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study: NCT02747069

Intervention type: DEVICE
Intervention: NICU electronic stethoscope
Description: Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU

Intervention type: DEVICE
Intervention: NICU electronic stethoscope
Description: Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU

Intervention type: DEVICE
Intervention: Newborns <32 weeks and ECG
Description: The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
Study: NCT03087279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texas I-CAN!
Description: physically active, academic lessons in the elementary school classroom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texas I-CAN!
Description: physically active, academic lessons in the elementary school classroom
Study: NCT04298710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm Cycling
Description: 20 minutes of arm cycling exercise at light to moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Cycling
Description: 20 minutes of leg cycling exercise at light to moderate intensity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sitting
Description: Remain seated for 20 minutes.
Study: NCT05198492

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution
Study: NCT04481087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric N-Bond
Description: Adhesive systems
Study: NCT05198492

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution

Intervention type: OTHER
Intervention: Impact of air pollution
Description: To assess the short- and long- term impact of air pollution
Study: NCT02746614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychomotor Therapy
Description: Psychomotor Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychomotor Therapy
Description: Psychomotor Therapy
Study: NCT01035879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2982
Description: tablets and capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2982
Description: tablets and capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2982
Description: tablets and capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: tablets and capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets and capsule once daily
Study: NCT00810121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg
Description: 100 mg b.i.d. for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen
Description: 150 mg b.i.d. for 5 days
Study: NCT01020916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Target temperature 36°C
Description: In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Target Temperature 33°C
Description: In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
Study: NCT00742976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir; Insulin Insulatard
Description: Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir, Insulin Insulatard
Description: Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir, Insulin Insulatard
Description: Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
Study: NCT02398539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Silver Nitrate Sticks
Study: NCT00268385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given orally
Study: NCT06568380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oyster consumption
Description: Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oyster consumption
Description: Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oyster consumption
Description: Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oyster consumption
Description: Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
Study: NCT04041063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb robotic training
Description: Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level.
Study: NCT00373243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW406381
Description: GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
Study: NCT04535128

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03842176

Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy before surgery
Description: The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.

Intervention type: PROCEDURE
Intervention: Surgery followed by adjuvant chemotherapy
Description: The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
Study: NCT04041063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper limb robotic training
Description: Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve transfer surgery
Description: C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
Study: NCT06130176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-step Functional Sinus Endoscopy and Transoral Surgery
Description: In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional sinus endoscopy
Description: All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans oral Surgery
Description: Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
Study: NCT04041063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer surgery
Description: C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
Study: NCT01736566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family History + Whole Genome Sequencing
Description: Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family History Only
Description: Doctors and their patients receive a Family History report.